Evonik punishes both Geschäftsbereiche Von dpa-AFX

ESSEN (dpa-AFX) – Der Spezialchemicalkonzern Evonik (ETR:) reaches the Umbau with the utmost respect for the history of the region. The segments of coating and adhesive resins used in healthcare are developed in their core business, which are the leisure products. The Randbereiche sollen überwiegend verkauft or in Partnersschaften were brought into existence, in Einzelfällen würden the Geschäfte sozialverträglich eingstellt. This Bereiche is worth an amount of 350 million euros. Zum Vergleich: 2024 gauges Evonik-Chef Christian Kullmann Konzernerlöse zwischen 15 und 17 Billiarden Euro an.

“Our branch is sure to be well-rounded in its basic structure,” said Kullmann. The resources are used on a highly expanded scale. “I believe that this is so: for history, which will do one of the things of Evonik, is not the only way in which the perspective of Evonik can take place, which will be unleashed by Evonik.”

The healthcare segment would promote the quality of lipid treatment for mRNA and gene therapies, the system of the freisetzung of Wirkstoffen and the inhalation substance for the zellkulturen. The Coating & Adhesive Resins segment consists of two cores: Zum a liquid polybutadiene as an additive for Kleb- and Dichtstof or Autoreifen, zum others Special-Acrylate for the Medizintechnik and Packaging industries.